Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan + Chemotherapy in Chinese R/R AML
NCT05054543Phase 3Terminated
- Sponsor
- Apollomics, Inc.
- Start
- Nov 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Uproleselan Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival at 3 years. Started Nov 2021; status: terminated.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05054543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054543.